Omrix biopharmaceuticals Ltd., J&J sales and marketing update

Johnson & Johnson Wound Management, a division of JNJ's Ethicon Inc. subsidiary, received exclusive North American marketing and distribution rights to Omrix's Crosseal (Human) bovine component-free ...